Riskpilot← Back to searchSign inGet full accessIpotek AB
ABActiveOrg 5567861397Fornvägen 8Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20090 employees
Revenue 2024
SEK 130K
-95% vs 2023
EBITDA margin
-382.3%
-128% vs 2023
Equity ratio
44.0%
Financial strength
Net profit 2024
SEK -43K
-104% vs 2023
| Revenue | SEK 130K | -95% |
| EBITDA | SEK -497K | -128% |
| Net profit | SEK -43K | -104% |
| Total assets | SEK 2,2M | -11% |
| Equity | SEK 953K | -18% |
| Employees | 0 | — |
Legal name
Ipotek AB
Org number
5567861397
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16 juli 2009
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva konsultverksamhet inom läkemedel,import och export av läkemedel och medicinska artiklar. Samt Detaljhandel för Läkemedel. Företaget kommer även importera och exportera diverse varor så som elektronik och kommunikation och tele utrustning.
Address
Fornvägen 8
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 81 | 141 | 449 | 2 771 | 130 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −61 | −50 | −119 | 1 801 | −497 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −61 | −50 | −119 | 1 801 | −497 |
| Net financials | — | — | — | — | 3 |
| Profit before tax | −39 | −50 | −119 | 1 351 | −43 |
| Tax | −0 | −0 | −0 | −297 | −0 |
| Net profit | −39 | −50 | −119 | 1 054 | −43 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 212 | 223 | 543 | 2 445 | 2 168 |
| Equity | 111 | 111 | 113 | 1 157 | 953 |
| Long-term debt | 81 | 64 | 61 | 671 | 0 |
| Short-term debt | 20 | 48 | 369 | 1 509 | 1 214 |
| Total debt | 101 | 112 | 430 | 2 180 | 1 214 |
EBITDA margin
-382.3%
This company
15.8%
Market median
-2520% vs market
20202024
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20202024
Return on equity
-4.5%
This company
18.4%
Market median
-124% vs market
20202024
Net profit margin
-33.1%
This company
8.1%
Market median
-509% vs market
20202024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20202024
Debt / equity
1.27×
This company
0.62×
Market median
-105% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ipotek AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mojgan Mehdizadeh | Deputy Board Member | 0 companies |
| Kourosh Lotfi | Board of Directors | 0 companies |